Abbott Laboratories (ABT) financial statements and ratios from SEC XBRL: revenue $44.33B (TTM), net margin 14.7%, revenue growth 7.8% YoY, P/E 31.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $44.33B |
| Net Margin | 14.7% |
| Return on Equity | 11.9% |
| Debt / Equity | 0.65 |
| Current Ratio | 1.39 |
| Revenue Growth (YoY) | 7.8% |
| EPS Growth (YoY) | -18.4% |
| FCF Growth (YoY) | -1.8% |
| P/E Ratio | 31.7 |
| EV / EBITDA | 24.6 |
| Price / Book | 3.78 |
| Price / Sales | 4.41 |
| Dividend Yield | 2.1% |
| FCF Yield | 3.7% |
| DCF Value (model) | $47.53 |
| DCF Upside vs Price | -58.4% |
| Altman Z-Score | 5.26 (safe) |
| Piotroski F-Score | 5/9 |
| Sector P/E (Healthcare) | 21.6 |
ABT overview · ABT earnings · ABT KPIs · ABT investor relations · ABT ownership · ABT peers · ABT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.